Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.
A feature article published in Evidence-Based Oncology™, a special issue publication of The American Journal of Managed Care® (AJMC®), was highlighted in a piece by Stat. The article, “As Myeloma Trials Tackle Frontline Treatment, Where Are the Black Patients?” highlighted the lack of diversity in a recent phase 3 clinical trial for isatuximab, a treatment approved for multiple myeloma. The clinical trial had among the lowest rates of Black participants in the past 2 decades.
An article from Becker’s ASC Review highlighted conference coverage published on AJMC.com, the website of AJMC. The article, “Vertical Integration in Cardiology Brings Less Value, Analysis Finds,” reported on a poster session held at the American Heart Association Scientific Sessions 2024, where presentations included the finding that vertical integration has led to higher costs in Medicare with little evidence of an increase in quality.
An article from Midland Daily News referenced an article published on AJMC.com. The article, “Infant Mortality Increases Across US Following Dobbs Decision,” reported that a 7% absolute increase in overall infant mortality and a 10% increase in infants with congenital anomalies has occurred following the Dobbs decision made by the Supreme Court, which overturned the Roe v Wade ruling that had guaranteed the legality of abortion.
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
Laundromats as a New Frontier in Community Health, Medicaid Outreach
May 29th 2025Lindsey Leininger, PhD, and Allister Chang, MPA, highlight the potential of laundromats as accessible, community-based settings to support Medicaid outreach, foster trust, and connect families with essential health and social services.
Listen
Zanubrutinib Shows Durable Benefit for High-Risk CLL/SLL at 5 Years in SEQUOIA Trial
June 6th 2025Zanubrutinib showed long-term efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and deletion of the 17p chromosome, with progression-free survival similar to patients without high-risk disease characteristics.
Read More